跳到正文
原文
Medical Xpress·· 24 天前精选AI 评分64

108例自身免疫病CAR-T队列:基线B细胞计数与IL-6水平与细胞因子释放综合征风险相关

Biomarkers identified for cytokine release syndrome risk after CAR T-cell therapy

AI 导读

一项发表于The Lancet Rheumatology的回顾性队列研究纳入108例接受自体CAR-T细胞治疗的自身免疫病患者,其中80%出现细胞因子释放综合征(CRS)。

推荐理由

回顾性队列在108例自身免疫病患者中给出CAR-T后CRS的基线生物标志物关联,可供风险分层参考。

正文
biomarker research
Credit: Unsplash/CC0 Public Domain

For patients with autoimmune disease, higher baseline B-cell counts and systemic inflammation are associated with development of cytokine release syndrome (CRS) after chimeric antigen receptor (CAR) T-cell therapy, according to a study published in the November issue of The Lancet Rheumatology.

Shirley Chiu Wai Chan, M.B.B.S., from Universitätsklinikum Erlangen in Germany, and colleagues conducted a retrospective cohort study in patients with autoimmune diseases treated with autologous CAR T-cell therapy from six centers in Germany and one in China to identify biomarkers predicting incidence and severity of CRS.

A total of 108 patients with autoimmune diseases who received autologous CAR T-cell therapy between March 1, 2021, and July 1, 2025, were included. The researchers found that 80% of patients developed CRS after CAR T-cell therapy (grades 1, 2, and 3 in 66%, 13%, and 1%, respectively). Three patients (3%) developed immune effector cell–associated neurotoxicity syndrome (grades 1 and 2 in 2% and 1%, respectively).

Compared with patients without CRS, those who developed CRS had significantly higher baseline B-cell counts, interleukin (IL)-6 concentrations, and C-reactive protein concentrations. The association between CRS and B-cell counts and IL-6 concentrations was confirmed in multivariable logistic regression (odds ratios, 1.31 and 2.28, respectively).

"These data ... support the biomarker-based identification of populations at increased risk for CRS that might be tackled with preventive treatment or more intense monitoring before and after CAR T-cell administration," the authors write.

Several authors disclosed ties to the biopharmaceutical industry.

Publication details

Shirley Chiu Wai Chan et al., Predicting prevalence and severity of cytokine release syndrome after CAR T-cell therapy in patients with autoimmune disease: a retrospective cohort study, The Lancet Rheumatology (2026). DOI: 10.1016/s2665-9913(26)00230-4

Journal information: The Lancet Rheumatology

Clinical categories

RheumatologyOncology

Who's behind this story?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

© 2026 HealthDay. All rights reserved.

Citation: Biomarkers identified for cytokine release syndrome risk after CAR T-cell therapy (2026, October 26) retrieved 26 October 2026 from https://medicalxpress.com/news/2026-10-biomarkers-cytokine-syndrome-car-cell.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com